Pharmaceutical composition for treating diarrhea-predominant irritable bowel syndrome

Abstract

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a pharmaceutical composition for treating diarrhea-predominant irritable bowel syndrome. The pharmaceutical composition provided by the invention comprises the following raw materials in parts by weight: 6-12 parts of baked ginger, 12-18 parts of fried bighead atractylodes rhizome, 9-15 parts of friedwhite paeony root, 3-9 parts of divaricate saposhnikovia root, 6-12 parts of smoked plum, 3-9 parts of valeriana jatamansi jones and 3-9 parts of coptis chinensis. The monarch drugs of bighead atractylodes rhizome and baked ginger and the minister drugs of dark plum and white paeony root in the formula are used for treating the pain and diarrhea; auxiliary medicines of valeriana jatamansi jones, divaricate saposhnikovia root and coptis chinensis are used for treating symptoms; all the medicines are compatible with one another, so that both symptoms and root causes are treated, and the composition is the meaning of a formula for simulating pain and diarrhea, and has the effects of strengthening the spleen, soothing the liver, regulating qi activity and stopping pain and diarrhea.

Description

technical field [0001] The invention belongs to the field of traditional Chinese medicine, and in particular relates to a pharmaceutical composition for treating diarrhea-type irritable bowel syndrome. Background technique [0002] Transient receptor potential vanilloid-l (TRPV1) is a ligand-gated non-selective cation channel protein, 2+ With high permeability, it can be activated by intracellular or extracellular mechanical, temperature and chemical stimuli, resulting in hyperalgesia and pathological pain. As a nociceptive molecule necessary for pain perception transmission, it plays a key role in the occurrence of visceral hypersensitivity in irritable bowel syndrome (Irritable Bowel Syndrome, IBS). Studies have confirmed that increased visceral sensitivity is a key factor in the pathogenesis of this disease. Clinical studies have shown that the expression of TRPV1 in the sigmoid colon of IBS patients is higher than that of normal people, and is positively correlated wit...

AI Technical Summary

Problems solved by technology

[0005] The purpose of the present invention is to solve the defect in the prior art that there is no traditional Chinese medicine composition that can directly affect the level of SP and CGRP in the patient's plasma and reduce the expression of TRPV1, and then provide a new pharmaceutical composition that fundamentally alleviates the Treating IBS Conditions

Images